Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 8337 - 8344 of 12142 results
NYC Extends Tax Credit Available to Biotech Companies
May 4, 2016| Alert| Viewpoint
Not Obvious to Combine for a Person of Ordinary Skill in the Art (POSITA)
May 3, 2016| Blog| Viewpoint
New Compounding Policies from FDA May Affect Hospital and Health System Pharmacy Operations
May 3, 2016| Blog| Viewpoint
CMS Releases Proposed Rule for MACRA Implementation – Overview and Merit-Based Incentive Payment Systems (MIPS)
May 3, 2016| Blog| Viewpoint
The New York Times: In 11 Missing Words, Some See Shift in NCAA Case Against UNC
May 3, 2016| Blog| Viewpoint
USCIS Completes the H-1B Cap Lottery Selection Process and Data Entry for Fiscal Year 2017
May 3, 2016| Alert| Viewpoint
Update: Vivendi Wins Summary Judgment Against Another Class Member As Litigation Winds Down
May 3, 2016| Blog| Viewpoint
FY2017 Massachusetts Budget Update: The House Budget
May 2, 2016| Alert| Viewpoint
News & Press Releases
Mintz Advises Point72 and Tsunami Express Car Wash in Acquisition of 53 Car Wash Locations from Whistle Express Car Wash
September 16, 2025
Mintz advised Point72 and Tsunami Express Car Wash, its portfolio company, in Tsunami’s acquisition of 53 car wash locations from Whistle Express Car Wash, which is owned by affiliates of Oaktree Capital Management.
Mintz Advises Charlesbank Capital Partners on Acquisition of Q6 Cyber
September 15, 2025
Mintz Advises on LB Pharmaceuticals’ $285 Million Initial Public Offering
September 12, 2025
Mintz advised the underwriters in connection with a $285 million initial public offering by LB Pharmaceuticals Inc of 19,000,000 shares of common stock at an initial public offering price of $15.00 per share. The aggregate gross proceeds to LB Pharmaceuticals from this offering were approximately $285 million before deducting underwriting discounts and commissions and other offering expenses. In addition, LB Pharmaceuticals granted the underwriters a 30-day option to purchase up to an additional 2,850,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. The shares began trading on the Nasdaq Global Market on September 11, 2025 under the ticker symbol “LBRX.”
Events
Podcasts
Mintz On Air: Practical Policies – DEI Developments: The Proxy Problem
September 16, 2025| Podcast|
Mintz On Air: Practical Policies – Disparage Me Not
August 26, 2025| Podcast|
Mintz On Air: Practical Policies - Investigations Unscripted
August 12, 2025| Podcast|